Jennifer Greenheck
Family · New Orleans, LANPI 1396871158
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 71.4% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $7,506, more than ten times the $185 reported in 2021. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $67.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$10K
- AstraZeneca$1K
- GSK$745
- Regeneron Healthcare Solutions, Inc.$675
- Boehringer Ingelheim$298
- Verona Pharma, Inc.$251
- plus $913 from 22 others
What the payments were for
- Consulting fees$6,64845%
- Travel & lodging$1,98214%
- Food & beverage$6,02041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 53 | $10,466 |
| AstraZeneca | 36 | $1,302 |
| GSK | 47 | $745 |
| Regeneron Healthcare Solutions, Inc. | 22 | $675 |
| Boehringer Ingelheim | 10 | $298 |
| Verona Pharma, Inc. | 8 | $251 |
| Mylan Specialty L.p. | 6 | $125 |
| Baxter Healthcare | 5 | $119 |
| Insmed, Inc. | 5 | $98 |
| Amgen | 3 | $60 |
| Electromed, Inc. | 2 | $50 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Merck | 2 | $47 |
| Viatris Specialty LLC | 2 | $43 |
| Calliditas Therapeutics US Inc. | 2 | $41 |
| Pinnacle Biologics, Inc | 1 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $22 |
| Phadia US Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Olympus America Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,650 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 213 | $154,164 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 190 | $140,241 |
| Dupixent PenDupilumab | 15 | $57,199 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 104 | $54,721 |
| Spiriva RespimatTiotropium Bromide | 72 | $51,624 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $18,924 |
| OzempicSemaglutide | 13 | $11,968 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $11,012 |
| Serevent DiskusSalmeterol Xinafoate | 24 | $10,145 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 307 | $7,896 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,302 |
| Ventolin HfaAlbuterol Sulfate | 28 | $1,526 |
| Fluticasone Propionate | 65 | $1,338 |
| Azithromycin | 27 | $701 |
| Levocetirizine Dihydrochloride | 77 | $440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $745 | $173,088246 claims |
| AstraZenecaBreztri Aerosphere | $1,302 | $140,241190 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $298 | $117,358190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in New Orleans
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Amy SchmittNew Orleans$48K
- Eric BabineauxNew Orleans$32K
- Cherie AlbroNew Orleans$29K
- Aimee ScroggsNew Orleans$20K
- Kelly BaquetNew Orleans$18K
- Lori LemoineNew Orleans$17K
- Joseph DefraitesNew Orleans$13K
- Rebecca EzellSlidell$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.